Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5507007

CCCc1cnc2ccccc2c1.N

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.53
PDE10A Q9Y233 8/20 0.53
CYP1A2 P05177 2/20 0.52
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
KDM1A O60341 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6115113 0.98 TRPV1 (0.55) TRPV1PDE10ACYP1A2PDGFRBPDGFRA
SCHEMBL6114503 0.88 PDE10A (0.60) TRPV1PDE10ACYP1A2PDGFRBPDGFRA
SCHEMBL3396692 0.87 CYP1A2 (0.55) PDE10ACYP1A2PDGFRBPDGFRAKDM1A
SCHEMBL859430 0.86 TRPV1 (0.56) TRPV1PDE10ACYP1A2MEN1KMT2A
SCHEMBL6114605 0.85 TRPV1 (0.58) TRPV1PDE10ACYP1A2MEN1KMT2A
SCHEMBL6114625 0.85 TRPV1 (0.58) TRPV1PDE10ACYP1A2MEN1KMT2A
SCHEMBL6115263 0.85 TRPV1 (0.58) TRPV1PDE10ACYP1A2MEN1KMT2A
SCHEMBL6114660 0.85 TRPV1 (0.58) TRPV1PDE10ACYP1A2MEN1KMT2A
SCHEMBL6114969 0.85 TRPV1 (0.58) TRPV1PDE10ACYP1A2MEN1KMT2A
SCHEMBL6114751 0.85 TRPV1 (0.58) TRPV1PDE10ACYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100460415-C Ketolactones, their use and process for their preparation and pharmaceutical compositions containing them ABBOTT LAB (US) 2009-02-11 CN disclosed
CN-100441591-C Ketolactones, their use and process for their preparation and pharmaceutical compositions containing them ABBOTT LAB (US) 2008-12-10 CN disclosed
US-RE39836-E1 Macrolide antinfective agents KOSAN BIOSCIENCES, INC. (US) 2007-09-11 US disclosed
US-RE39591-E1 6-O-substituted ketolides having antibacterial activity ABBOTT LABORATORIES (US) 2007-04-24 US disclosed
EP-1171446-B1 MACROLIDE ANTIINFECTIVE AGENTS KOSAN BIOSCIENCES INC (US) 2006-09-20 EP disclosed
CN-1273475-C 6-0-substituted ketolides with antibacterial activity ABBOTT CO (US) 2006-09-06 CN disclosed
EP-1291351-B1 6-0 substituted ketolides having antibacterial activity ABBOTT LAB (US) 2005-07-13 EP disclosed
EP-1291353-B1 6-O-substituted ketolides having antibacterial activity ABBOTT LAB (US) 2005-06-01 EP disclosed
EP-0929563-B1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LAB (US) 2005-06-01 EP disclosed
EP-1291350-B1 6-0 substituted ketolides having antibacterial activity ABBOTT LAB (US) 2005-05-25 EP disclosed
US-20020119938-A1 Macrolide antiinfective agents CHU DANIEL (US) 2002-08-29 US disclosed
US-6395710-B1 CONTROLLING INFECTIONS KOSAN BIOSCIENCES, INC. 2002-05-28 US disclosed
US-20020055472-A1 Macrolide antiinfective agents KOSAN BIOSCIENCES, INC. 2002-05-09 US disclosed
WO-2001049699-A1 MACROLIDE ANTIINFECTIVE AGENTS KOSAN BIOSCIENCES, INC. (US) 2001-07-12 WO disclosed
US-6147197-A INCREASED ACID STABILITY AND ENHANCED ACTIVITY TOWARD GRAM NEGATIVE BACTERIA AND MACROLIDE RESISTANT GRAM POSITIVE BACTERIA ABBVIE INC. 2000-11-14 US disclosed
US-6075133-A INCREASED ACID STABILITY AND ENHANCED BACTERICIDAL ACTIVITY ABBOTT LABORATORIES (US) 2000-06-13 US disclosed
CN-1237183-A 6-0-substituted ketolides with antibacterial activity ABBOTT CO (US) 1999-12-01 CN disclosed
EP-0929563-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY Abbott Laboratories (US) 1999-07-21 EP disclosed
US-5866549-A MACROLIDE ANTIBIOTICS ABBOTT LABORATORIES (US) 1999-02-02 US disclosed
WO-1998009978-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119938-A1 Macrolide antiinfective agents MLNR, DOHH, NOP2 TRPV1 3701/4885PDE10A 3776/4885CYP1A2 2938/4885
US-20020055472-A1 Macrolide antiinfective agents BECN1, HSPA5, SQSTM1 TRPV1 1098/4885PDE10A 4538/4885CYP1A2 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.